Caduet's Japanese price may set precedent for combinations
This article was originally published in Scrip
Pfizer's combination cardiovascular product Caduet, Novartis's novel antihypertensive Rasilez and other products have been awarded prices in Japan and will be added to the reimbursement tariff on September 4th, clearing the way for launch.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.